American Pharmaceutical Partners $4.1 billion Acquisition
Represented American Pharmaceutical Partners, a public pharmaceutical company, in its $4.1 billion acquisition of privately-held American Bioscience.
American Pharmaceutical Partners $160 million IPO
Represented American Pharmaceutical Partners in its $160 million initial public offering. Prior to the IPO, Mr. Farman represented APP in its $52 million Series A-D preferred stock financings, its $75 million acquisition of a generic pharmaceutical company, and various other equity and debt financings, business acquisitions, and strategic collaborations.
Abraxis Bioscience $2 billion Spin-Off
Represented Abraxis Bioscience, a public company, in the spin-off of a new $2 billion public company focused on biopharmaceuticals.
OSI $700 million Acquisition by Agilent
Represented Objective Systems Integrators, a public telecommunications software company, in a $700 million cash tender offer acquisition by Agilent Technologies.
Private Equity Funds - Investors
Represented institutional investors in the formation of over 300 domestic and foreign private equity funds, with per-investor commitments ranging from $5 million to $600 million. In the last three years alone, Mr. Farman has represented limited partner investors in their investment of more than $10 billion in over 50 funds having an aggregate committed capital in excess of $200 billion. Mr. Farman has represented significant limited partner investors in 10 of the 15 largest private equity funds ever formed.
Private Equity Funds – General Partners
Represented general partners/fund managers in the formation of over 40 private equity funds and funds-of-funds with aggregate committed capital in excess of $7 billion.
Financings of Emerging Growth Companies
Represented venture capital funds, other institutional investors, and various start-up and emerging-growth technology companies, in over 50 preferred stock financings and other private equity investments.